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Abstract:
Chromosomal microarray (CMA) assesses chromosome copy number variants
(CNVs) missed by standard karyotyping. The American College of Obstetricians and
Gynecologists (ACOG) recommends CMA for all patients with fetuses with an
ultrasound anomaly and suggests that it be made available to all women undergoing
invasive testing. In order to assess prenatal genetic counselors’ (GCs) practices
regarding the utilization of CMA we conducted a survey of their current practices,
attitudes, and perceived barriers. Of the 192 respondents, 183 (95%) have
incorporated CMA into clinical practice with the majority (64%) believing that the
benefits of CMA outweigh the harms. However, only half (52%) of the respondents
agreed that CMA should be offered to all women regardless of indication. The
respondents who reported feeling that they were experts/comfortable in their
knowledge of CMA (85%) and were familiar with current clinical guidelines (86%)
were significantly more likely to offer CMA to all patients undergoing invasive testing,
patients with fetuses with anomalies, and those referred for advanced maternal age.
Genetic counselors report not offering CMA to patients due to patient specific
concerns (51%), such as anxiety or health literacy, financial concerns (39%),
iv

difficulty of interpreting results (39%), lack of data (36%), and time constraints
(22%). Patient specific concerns were the largest reported barrier when GCs chose
not to offer CMA to patients which, is different than the studies which predate the
ACOG guidelines that cited financial and ethical concerns as barriers. Our study
demonstrates that GCs follow established guidelines for use of CMA when specific
indications are involved but further guidelines are needed regarding use of CMA for
other common prenatal indications. Based on this, other professional societies such
as National Society of Genetic Counselors should consider publishing guidelines on
prenatal CMA that are specialized to the GCs sphere of practice.
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Introduction
Chromosomal microarray analysis (CMA) is a genetic test that can identify
chromosomal aneuploidy as well as chromosomal microduplications and
microdeletions, referred to as copy number variants (CNVs). CNVs are often too
small to be detected by a conventional karyotype, but are implicated as a cause of
multiple genetic disorders that may manifest as congenital anomalies or a fetal
demise during pregnancy 1.
CMA has been used in pediatric and adult genetic clinics for over a decade,
and the American Academy of Pediatrics recommends CMA as a first-tier test for
individuals with autism spectrum disorder, developmental delay, unexplained
intellectual disability, and multiple congenital anomalies 2.
In 2012 a multi-center prospective trial conducted by the National Institute of
Child Health and Human Development (NICHD) showed that, in the presence of a
normal karyotype, approximately 6% of pregnancies with fetal anomalies detected
on ultrasound, and 1.7% of pregnancies with routine indications, such as advanced
maternal age, had clinically significant CNVs detected on prenatal CMA 3.
Subsequent studies showed higher detection rates of CNVs, 6.5% in the presence of
an abnormal fetal ultrasound, and 8.2% in the presence of fetal demise 1.
Based on this, the American College of Obstetricians and Gynecologists
(ACOG), in conjunction with the Society for Maternal and Fetal Medicine (SMFM),
published a joint statement in 2013 recommending CMA as the first-line test when a
prenatal ultrasound shows one or more major fetal abnormalities 4. Guidelines also
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recommend CMA as the preferred genetic test to help identify the cause of fetal
demise and stillbirth, and that CMA should be made available to any patient
undergoing diagnostic testing 4. This was later reinforced by the updated 2016
ACOG and SMFM practice bulletin which further stated that CMA should be a
primary test, replacing karyotype, for patients with fetal structural abnormalities 5.
However, more prospective studies are needed to demonstrate the diagnostic utility
and benefit, as well as cost effectiveness of prenatal microarray in all pregnant
women.
One major complication with the technology of prenatal microarray is the
detection of CNVs of unknown significance, also referred to as variants of uncertain
significance (VUS), and the difficulty of interpreting VUS results 6. The overall VUS
rate in prenatal CMA is reported to be 1.5%-1.6% 7, 8. Information regarding CNVs
that are detected prenatally or in healthy individuals is very limited. In the hopes to
improve these gaps, several databases, such as ClinVar and DECIPHER, have
been established to help collect and distribute such information 9, 10. Parental or
family studies can aid in reclassification of variants given that CNVs inherited from
an unaffected parent tend to be benign, however, parental blood samples are not
always available for analysis, and incomplete penetrance cannot be excluded

11.

For

patients undergoing prenatal microarray testing, the uncertainty about the predicted
clinical phenotype and lack of precise risk estimate associated with VUS, particularly
in the absence of congenital abnormalities, may increase parental and family anxiety
and distress, as well as impact decision making regarding the pregnancy 15.
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Additionally, studies on cost effectiveness of CMA in prenatal diagnosis are
limited. Test coverage by insurance companies also varies. While many insurance
providers deem CMA to be “medically appropriate and/or necessary” in cases of
fetal structural abnormalities, many insurance companies still consider CMA to be
“investigational” or “experimental” and are not routinely covering the testing
especially in the absence of ultrasound abnormalities or other high risk factors

12-14.

Appropriate pretest and posttest genetic counseling, with a thorough
discussion of the benefits and limitations, is warranted for patients undergoing
prenatal microarray. ACOG recommends that certain points should be shared with
the patients prior to undergoing CMA and these include, but are not limited to, that
results may or may not be informative in terms of identifying a known genetic
condition, conditions detected by CMA may have high variability in clinical
presentation, may identify consanguinity or non-paternity, and that results may
identify adult-onset disease 7.
While discussion and ordering of prenatal CMA can be done by various
healthcare providers, genetic counselors are a subgroup of health professionals who
are uniquely trained in counseling regarding the benefits, limitations, and risks
associated with prenatal screening and testing options. Genetic counselors who
counsel patients frequently order prenatal tests, interpret and disclose these results,
and facilitate decision making and coordination of care following the results. Several
studies have therefore looked at the experiences and attitudes of genetic counselors
toward prenatal microarray.

3

A 2012 survey of 160 prenatal genetic counselors practicing in North America
showed that the majority (73%) of respondents found prenatal microarray to be a
useful tool, and 84% presented it to patients as a prenatal diagnostic option, but only
69% reported to have ordered a prenatal microarray at least once. Reported
challenges included financial issues and ethical concerns, as well as the difficulty of
interpreting uncertain results and explaining these complex results to patients

16.

Another study of 193 prenatal genetic counselors found that only 59% of counselors
would be comfortable providing genetic counseling and 43% would be comfortable
helping a patient make a decision about pregnancy termination in the presence of an
uncertain microarray result 17.
The above cited literature regarding the attitudes and practices of genetic
counselors regarding microarray testing largely predate the ACOG guidelines
released in December of 2013 4 and all predate the recent 2016 practice bulletin 5.
The current study aims to evaluate whether prenatal genetic counselors have
incorporated prenatal microarray into their clinical practice within the framework of
current guidelines, as well as their current practices regarding test ordering, pretest
counseling, and informed consent. The study will clarify prenatal genetic counselor
utilization as well as knowledge, beliefs, and perceived barriers toward
implementation of prenatal microarray into clinical practice.

Methods
This study was approved by the Committee for the Protection of Human
Subjects at the University of Texas McGovern Medical School at Houston (#HSC4

MS-16-0520). This was a survey based cross-sectional study of English-speaking,
board certified or eligible genetic counselors who currently practice prenatal genetic
counseling and discuss prenatal diagnostic testing options with patients. Participants
for the study were recruited via an email to the members of the National Society of
Genetic Counselors (NSGC). Participation was voluntary. Members who agreed to
participate by providing informed consent were asked to complete an anonymous
online survey. The incentive for the completion of survey was that the participants
were given the option of providing their email address in a separate email apart from
the survey if they wished to enter a drawing for a gift card.
The survey was created, distributed, and managed using Qualtrics online
software (Qualtrics, Provo, Utah) approved for use by the University of Texas
McGovern Medical School at Houston Institutional Review Board. The survey was
created for the study but did not employ formal or validated measures. There were
two arms to the survey, Arm A and Arm B, depending on if the participants did not or
did incorporate CMA into their prenatal practice, respectively. The questions
consisted of multiple choice, Likert scale, and free responses and were designed to
assess demographic information, knowledge and beliefs, current practices of
prenatal genetic counselors in regards to the use of CMA, and perceived barriers.
The initial email was sent to the NSGC membership August 1, 2016 and a second
reminder email was sent on September 12, 2016. Data collection was closed
October 1st and the survey link was deactivated. A full copy of the survey is available
in the Appendix.
Data Analysis
5

Descriptive statistics were presented as number (percentage) and mean ±
SD. Comparison of data generated from the survey questions was evaluated using
Pearson Chi-square analysis and Fisher exact test. Findings were considered
statistically significant if the p-value was <0.05 in this study. Data was analyzed
using STATA software (v.14.1, College Station, TX).

Results
At the time our survey was distributed there were 3,189 counselors registered
as members of NSGC. Of the 252 surveys that were started, a total of 192
participants completed the entire survey (76%). The open rate was 27.6% for the
first email and 26.3% for the second email. Per the 2016 professional survey, 43%
are prenatal counselors that practice in a clinical setting.
Demographics
The majority of the participants reported having less than 10 years of total
genetic counseling (70%) and prenatal specific genetic counseling (73%)
experience, spending over half of their time counseling patients in a clinical setting
(81%), and seeing more than 10 patients per week (69%). The greatest number
reported working at an institution that had 5 or less genetic counselors (73%), in a
university medical center or academic institution (40%), did not work for an institution
associated with a laboratory that performs prenatal CMA (74%), and did not work for
a center that provides fetal intervention (71%). A complete list of participant’s
demographics is summarized in Table 1. Most genetic counselors surveyed saw
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more patients with private insurance than Medicaid, state health insurance, and selfpay (Table 2).
Overall, the participants’ reported demographic information was
representative of the results gathered in the National Society of Genetic Counselors
2016 Professional Status Survey.
Table 1. Demographics
Demographics

N= 192

Percentage

Years of genetic counseling experience
<5

92

48%

6-10

42

22%

11-15

21

11%

16-20

18

9%

>20

19

10%

Years of prenatal genetic counseling experience
<5

105

55%

7

6-10

35

18%

11-15

21

11%

16-20

17

9%

>20

14

7%

Time spent counseling in the clinical prenatal setting
1-20%

20

10%

21-40%

17

9%

41-60%

25

13%

61-80%

34

18%

81-100%

96

50%

Prenatal patients seen per week
<5

24

13%

6-10

35

18%

11-15

64

33%

16-20

48

25%

>20

21

11%

8

Work setting
University Medical Center/Academic Institution

76

40%

Private Hospital/Medical Facility

45

23%

Public Hospital/Medical Facility

37

19%

Government or Military Hospital/Medical Facility

1

1%

Private Practice/Office

24

12%

Commercial Diagnostic Laboratory

5

3%

Other

4

2%

22

12%

32

17%

22

11%

48

25%

29

15%

Region of practice
Region 1:
CT, MA, ME, NH, NY, RI, VT, CN, Maritime Provinces

Region 2:
DC, DE, MD, NJ, NY, PA, VA, WV, PR, VI, Quebec

Region 3:
AL, FL, GA, KY, LA, MS, NC, SC, TN

Region 4:
AR, IA, IL, IN, KS, MI, MN, MO, ND,
NE, OH, OK, SD, WI, Ontario

Region 5:
AZ, CO, MT, NM, TX, UT, WY,
Alberta, Manitoba, Saskatchewan
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Region 6:

39

20%

AK, CA, HI, NV, ID, OR, WA, British Columbia

Number of prenatal genetic counselors at institution
0

40

21%

1-5

101

53%

6-10

28

15%

11-15

16

8%

>15

7

4%

Work in a center that provides fetal intervention
Yes

46

24%

No

137

71%

9

5%

Unsure

Work for a hospital/laboratory/commercial entity that
performs prenatal CMA
Yes

47

24%

No

141

74%

4

2%

Unsure
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Figure 1.

Percentage of Patients Seen with the Following Insurance
Coverage (n=192):
200
180
160
140
120
100
80
60
40
20
0

Medicaid

Private Insurance
0-24%

25-49%

Other state health
insurance (i.e. CHIP)
50-74%

Self-Pay

75-100%

Knowledge and Beliefs
Participants were asked to describe their current level of knowledge regarding
prenatal CMA, with most reporting they felt they were either an expert and could
teach others, or that they were comfortable ordering the test without further
education (n=163, 85%). The majority reported to be current with clinical guidelines
for the use of prenatal CMA (n=166, 86%). A little over half agreed that CMA should
be offered to all patients regardless of indication (n=99, 52%) and a larger portion
agreed that the benefits of CMA in its current form outweighed the harms (n=123,
64%) (Table 3).
11

Table 2. Knowledge and Beliefs
Knowledge and Beliefs

N= 192

Percentage

Level of knowledge regarding prenatal microarray
Expert

53

28%

Comfortable no need for further education

110

57%

Comfortable, would like more education

27

14%

Basic knowledge

1

0.5%

No knowledge

1

0.5%

Familiar with current clinical guidelines for prenatal microarray
Yes

166

86%

No

3

2%

Unsure

23

12%

I believe prenatal microarray should be offered to all women regardless of
indication
Agree/Somewhat agree

99

51%

12

Neutral

11

6%

Disagree/Somewhat disagree

82

43%

I believe that, in its current form, the benefits of prenatal microarray
outweigh the harms
Agree/Somewhat agree

123

64%

Neutral

38

20%

Disagree/Somewhat disagree

31

16%

Incorporation into Practice
Genetic counselors were asked if they had incorporated prenatal CMA into
their clinical practice by offering it as an option to patients, and the majority reported
that they have (n=183, 95.3%). Of the 9 participants who have not incorporated CMA
into their clinical practice (Arm A), when asked if they anticipated that they would
begin offering the test in the future, 5 were unsure when they would incorporate it
into use, and 2 reported they would incorporate it within the next 6 months. Only 1
stated that they did not plan on offering prenatal CMA in their clinical practice.
For those who have incorporated it into their practice (Arm B), detailed
questions were asked with the intent of evaluating their current utilization and
practices. We put forward sampled indications, modeled on ACOG guidelines or
based on indications genetic counselors might encounter in a clinical setting, and
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asked participants how frequently they offer prenatal CMA given that specific
indication by using a Likert scale. Results are summarized in Figure 2.
Figure 2.

Frequency Prenatal CMA is Offered Given the Following
Indication (n=183):
All patients with a structural fetal
anomaly
Patients with a positive NIPT for
microdeletion or microduplication

Patients with a personal or family history
of microdeletion or microduplication
Patients presenting with fetal demise or
stillbirth
Patients with a desire to know "all
information possible"
All patients undergoing invasive testing,
regardless of indication
All patients with a non-structural fetal
anomaly

Patients with a positive screening for
fetal aneuploidy
Patient of advanced maternal age
(AMA)
All patient undergoing genetic
counseling
0%

Mostly/Always

20%

Half the time

40%

60%

80%

100%

Rarely/Never
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The greatest number of participants, 95%, reported that they “mostly” or
“always” offer CMA to patients with a structural fetal anomaly and 0% reported to
“never” or “rarely” offering CMA for this indication. Eighty seven percent of the
participants reported to “mostly” or “always” offer CMA to patients presenting with a
fetal demise or stillbirth, and 71% reported to “mostly” or “always” offer CMA to their
patients undergoing invasive testing. The participants that were offering CMA to
patients undergoing invasive testing were significantly more likely to report feeling
comfortable in their knowledge of CMA and did not need further education (p=.011).
Participants who said they “rarely” or “never” offer CMA for fetal demise or
stillbirth (9%) were more likely to report that lack of data regarding yield and utility
was influential in not offering the test, and were more likely to disagree that CMA
should be offered to all patients, although these responses did not show statistical
significance (p=.435, p=.257). Participants who reported to “rarely” or “never” offer
CMA to patients undergoing invasive testing (20%) were significantly more likely to
report that the difficulty of interpreting results was influential in not offering this test
(p=.009) and were significantly more likely to disagree that CMA should be offered to
all patients (p<.001).
In general, the majority of participants reported “mostly” and “always” offering
prenatal CMA for most of the sample indications. The exceptions were that,
approximately an equal number of participants reported “rarely” or “never” (45%) and
“mostly” and “always” (44%) offering CMA in the case of advanced maternal age
(AMA), and 66% reported “rarely” or “never” offering CMA to all patient undergoing
prenatal genetic counseling. Those that “mostly” or “always” offer CMA for AMA
15

were significantly more likely to report being current with guidelines (p=.023) and
report being comfortable with their knowledge of CMA (p=.001).
Of the participants who are not offering CMA for all patients undergoing
counseling, this group was significantly more likely to report that patient specific
concerns influenced this decision (p=.047) as well as difficulty in interpreting results
(p=.009). Of the participants who are not offering CMA for all patients undergoing
counseling and for patients who are AMA, this group was significantly more likely to
disagree that prenatal CMA should be offered to all patients regardless of indication
(p<.001 and p<.001 respectively). Those who were “never” or “rarely” offering CMA
for AMA were significantly more likely to report desiring more education regarding
CMA (p=.001).
Additionally, of the participants who reported “never” or “rarely” offering CMA
to patients with non-structural abnormalities, a family history of microdeletion and
microduplication syndromes, positive screen for aneuploidy, and patients who want
all information possible, were more likely to say that lack of data plays a
moderate/high degree of influence when not offering CMA (p=.001; p=.035; p=.004,
p=.001, respectively).
Frequency of use of CMA was compared to other demographic information
provided by the participants, but no other statistically significant trends were
encountered.

16

Barriers
Of the 9 genetic counselors who have not incorporated prenatal CMA into
their practice, 89% (n=8) reported that financial concerns, as well as the possibility of
receiving uncertain or ambiguous results (89%, n=8), played a moderate to high
degree of influence, followed by difficulty of interpreting results (78%, n=7). In
comparison, this group reported that patient specific concerns, such as anxiety or
health literacy (89%, n=8), and time constraints (78%, n=7) had little influence. Due
to the small sample size, further statistical analysis could not be performed.
Several reasons for not offering CMA were also reported by the 183
participants who offer prenatal CMA, including patient specific concerns (51%),
financial concerns (37%), difficulty of interpreting results/lack of data (39%), and time
constraints (22%). For participants who cited financial concerns as the reason for not
offering CMA to patients, there were no statistically significant differences between
the types of insurance their patients reportedly had (p=.198, p=.670, p=.868).
Barriers were compared to other demographic information provided by the
participants, but no other statistically significant differences were encountered.
Results are summarized in Figure 3.

17

Figure 3.

Factors that Play a Role When Prenatal CMA is not offered
to the Patient (n=183):

Patient Specific Concerns

Difficulty of Interpreting Results

Lack of Data Regarding Yield/Utility

Financial Concerns

Time Constraints/Lack of Support Staff

0%

High Degree

10% 20% 30% 40% 50% 60% 70% 80% 90% 100%

Moderate Degree

Low Degree

No Influence

Pre-Test and Test Ordering Practices
Participants who have incorporated CMA into clinical practice were asked
how frequently they discussed certain points during pre-test counseling (Figure 4).
The points that were “mostly” or “always” discussed by the majority of participants
include: CMA can yield a pathogenic or abnormal result (99%), the severity of the
18

phenotype may not be predictable (96%), the results may be a VUS (96%), results
may have implications for the parents (74%), and results can show incidental
findings, such as non-paternity (68%). However, approximately half of participants
reported that they “rarely” or “never” discuss that results may indicated an adult
onset disorder (48%). Those that do not discuss adult onset disorders tended to
have less than 10 years of experience, but this was not statistically significant
(p=.072). This was also compared to other demographic information provided by the
participants, but no other statistically significant trends were encountered.
On average, 55% of participants who have incorporated CMA into their
practice reported ordering more than 10 prenatal CMAs per year and expanded
arrays were ordered more often than targeted arrays (64% vs. 33%). Most
participants (57%) reported ordering SNP arrays more frequently than
oligonucleotide arrays only (4%) or combination arrays (oligonucleotide with SNP,
30%). Those participants who ordered SNP arrays most often were less likely to
work for an entity that performs CMA (p=.001). GCs that work with 5 or less GCs at
their institution were significantly more likely to order SNP arrays (p=.001) while
those GCs who have 11+ GCs at their institution were significantly more likely to
order combination arrays (p=.001). Forty-five percent of participants reported
“mostly” or “always” ordering CMA in conjunction with a full karyotype, 25% reported
ordering CMA only with no accompanying karyotype, and 15% reported to ordering
CMA with a limited or 5 cell karyotype.

19

Approximately half of the participants reported only obtaining a verbal consent
when consenting patients for CMA (51%) followed by 43% that obtained both verbal
and written consent. Many participants felt that incorporating CMA into their
discussion during the session did not alter the length of an average genetic
counseling session, but that the length varied based on the case specifics or clinical
indication (55%). Fifteen percent reported that they, or their institution, participated in
data sharing, such as ClinGen, while 46% did not, and 39% were unsure. Those
who reported data sharing were significantly more likely to work for an academic
institution (p=.046). Working at a fetal center did not make a GC more likely to
participate in data sharing (p=.019) and neither did working for an institution that
performs CMA (p=.001).

20

Figure 4.

Frequency of Pre-Test Counseling Discussion Points for CMA
(n=183):
Result may be abnormal/pathogenic

Result may be a variant of known
signficance

Result may be abnormal/pathogenic but
not be predictable

Cost and Insurance coverage

Result may have implications for one or
both parents

Result may be an incidental finding
(ex.non-paternity)

Result may indicate an adult onset
disorder

0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%

Most/Always

Half the Time

Never/Rarely
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Resources
Participants were asked what resources they use to stay current on
information regarding prenatal CMA. The majority reported to stay current using the
guidelines or practice bulletins from professional organizations (n=176) followed by
information gathered at national or scientific meetings (n=160). The fewest number
of participants reported using marketing material from commercial laboratories to
stay current (n=52). In the free response section, several participants stated that
they utilize the expert knowledge and recommendations of laboratory genetic
counselors, and that discussions with their colleagues were an important resource.
Figure 5.

Resources Used to Stay Current on Information about
Prenatal Microarray
Guidelines or Practice Bulletins from
professional organizations

176

National or scientific meetings

160

Review articles by experts on the topic

139

Peer-reviewed journals

135

Marketing materials from commercial
laboratories

None of the above

51

1
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Discussion
This study provides a cross-sectional view of current prenatal genetic
counselors’ practices and utilization of prenatal CMA, as well as barriers and
challenges they encounter in North America. This is not the first study to evaluate
genetic counselors’ utilization, attitudes, and perceived barriers in relation to prenatal
CMA, but it is the first study since ACOG published their guidelines and
recommendations for its use in the prenatal setting.
This study demonstrates that nearly all prenatal genetic counselors surveyed
have incorporated prenatal CMA into their clinical practice by offering it to their
patients (95.3%), with most ordering more than 10 arrays per year (55%), and the
majority feeling very comfortable in their current knowledge of prenatal CMA without
desiring further education (83.3%). This differs from the 2012 surveys that found
only 84% of prenatal genetic counselors presented CMA to their patients, and that
genetic counselors desired more education and resources about prenatal CMA
testing 16, 17. This increase in utilization of prenatal CMA is likely due to a
combination of factors, including the availability of guidelines set forth by
professional organizations, number of discussions and presentations regarding CMA
at national conferences such as the NSGC’s Annual Education Conference, as well
as the publication of peer-reviewed studies which further demonstrated the utility of
CMA in the prenatal setting 2, 3, 8, 18-21.
This study also shows that the vast majority of genetic counselors surveyed
(95%) are offering prenatal CMA to patient’s whose fetus has been identified with a
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structural anomaly, 87% are offering CMA in the presence of stillbirth or fetal
demise, and 71% are offering CMA to all patients undergoing invasive testing
demonstrating that overall prenatal genetic counselors are practicing in concordance
with ACOG guidelines regarding utilization of CMA 7.
Genetic counselors, however, were much less likely to offer CMA to all
patients undergoing prenatal genetic counseling and those who are seen for routine
indications, such as AMA. ACOG guidelines do not explicitly “recommend” but state
that CMA “should be considered” for all women undergoing invasive testing, leaving
it up to the provider to decide who to offer it to 7. Most of the counselors who were
offering CMA to patients cited patient specific concerns, such as anxiety and health
literacy, as well as difficulty interpreting results as barriers to why they are not
offering CMA in these situations. Although patient specific concerns was a newly
reported barrier to offering prenatal CMA, the barrier of difficulty of interpreting
results has been repeatedly reported in previously published studies 16. Given the
likelihood of finding a clinically significant CNV in pregnancies with common
indications, like positive serum screening or AMA (1.3-1.7%), is similar to the
likelihood of finding a VUS on CMA (1.5-1.6%), and evidence that VUS results
significantly increase parental and family anxiety and distress3, 15, 22, this is not an
unreasonable concern. More studies are needed; however, to explore how genetic
counselors evaluate factors such as patient anxiety during a genetic counseling
session when they are deciding whether to offer CMA.
Recommendations on the type of pre- and posttest counseling patients
should receive prior to ordering a CMA have previously been recommended 6 and
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reiterated by ACOG 7. In our study, genetic counselors reported frequently reviewing
the recommended pre-test counseling discussion points with patients (Figure 4)
such as the types of results that CMA may yield. They also reported discussing
financial concerns, such as insurance coverage and cost of testing, before testing is
ordered. However, only about half of the genetic counselors reported discussing
those results may indicate an adult onset disorder, despite ACOG guidelines. It is
unclear from our study why this is so, but it may be due to the fact that at least 33%
of counselors reported primarily ordering targeted arrays, which may decrease the
chance of receiving these types of results. Further research into why certain results
are not discussed as regularly with patients as other types of results, and the genetic
counselors reasons for not doing so, would provide better insight into whether this
decision is based mainly on the type of array ordered, the time constraints of the
session, if it is a personal preference of the genetic counselor, or if there is a
combination of factors effecting this decision.
Unlike preivously published concerns 16, financial issues did not play as large
of a role when counselors did not offer CMA as it did in the past. Increasing
coverage of CMA testing by commercial insurance providers and the continually
decreasing cost of CMA testing may be contributing factors. Insurance companies
often conform to the recommendations of professional organizations, such as
ACOG, and begin to cover new services when such recommendations are
established 6. When published medical policies from a few major insurance carriers
were reviewed at the time this study was performed, many policies largely mirrored
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the language of the ACOG guidelines giving further evidence that insurance
companies often utilize national guidelines when deciding patient coverage.
Overall, our study demonstrates that prenatal genetic counselors, despite
practicing in many different settings and with varying years of experience, are
utilizing CMA within the context of clinical guidelines. Genetic counselors reportedly
follow pre-test counselling guidelines, believe that CMA is a useful test, and feel
comfortable with their knowledge of CMA. Despite this, over half still believe that
CMA should not be offered to all patients, regardless of indication, confirming the
fact that more studies are still needed on the utility of CMA for all pregnant women.
We did not observe a need for further education on CMA technology, as the
majority of counselors felt comfortable in their knowledge. However, the consistent
barrier to ordering CMA appeared to be patient specific concerns, such as anxiety
and health literacy. Therefore, further studies and education on CMA should
continue to focus on providing more information on those factors which influence
patient anxiety, such as receiving a VUS, and encourage more data sharing to
further minimize the risk of uncertain results. Current guidelines and previous studies
have alleviated earlier genetic counselors’ concerns on the utility and yield of
prenatal CMA for certain clinical indications, and have decreased certain barriers to
ordering CMA such as ethical concerns, but there is still a lack of data and
guidelines for how prenatal microarray should be utilized for other indications
commonly seen by prenatal genetic counselors.
At this time there are no studies that focus on the patient specific concerns
experienced by patients undergoing a discussion of prenatal microarray testing. A
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study looking at these patients concerns with an emphasis at teasing out what
exactly are the specific underlying causes of those concerns could provide more
information on how medical professions, specifically genetic counselors, could better
address these concerns during their conversations with patients. Professional
societies, particularly NSGC, may consider publishing guidelines that focus, not
necessarily on when it should be clinically indication, but more so on evaluating and
addressing patient specific concerns related to prenatal CMA. Established guidelines
from NSGC would allow GCs access to guidelines specialized to their sphere of
practice and further address some of the concerns noted in this study.
Study Limitations
This survey was distributed via email to the entire NSGC membership listserv
and may represent a skewed population. Genetic counselors who either are not
members of NSGC, or those who declined to receive student surveys, had their
practices, experiences, and voices excluded. With any study, there is the inherit
selection bias that those who take part may have an affinity for this subject matter or
have very strong opinions regarding CMA, which may make them more likely to
respond to the survey than those who find this subject less interesting. A large
portion of genetic counselors who responded to this survey (24%) reported working
at a center that offered fetal intervention, which is a higher number than expected
based on the number of fetal centers nationally, and may see a disproportionally
higher number of patients with ultrasound anomalies than those with standard
indications.
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Although our survey was distributed early in the fall semester, before the
usual onslaught of student surveys were released upon the NSGC membership,
there is the risk that we limited our participation because of survey fatigue
experienced by NSGC members. Our survey was also designed to have forced
responses, in other words, the participant could not move forward in the survey
before answering the current question. We had many partially completed surveys,
which were not included in our study, which may have been caused by this
mandatory response setting and fatigue from answering a longer survey.
It was also impossible to calculate a response rate for our study. Per the 2016
professional survey, 43% are prenatal counselors that practice in a clinical setting.
Based on how this survey was distributed, however, it is not possible to calculate
how many NSGC members meet our eligibility criteria or how many received and/or
opened the survey. This is because the email was sent to the entire NSGC
membership, but there is not accurate data kept on who within the membership
identify specifically as a clinical prenatal counselor. Because of this we only have the
email open rate, which is also skewed by the fact that genetic counselors of other
specialties, students, and other NSGC members opened the email. Additionally, the
study was not based on validated measures and may have caused misinterpretation
by the participants when answering the questions.
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Appendix
The Integration of Prenatal Microarray: A Survey of Current Genetic Counseling
Practices and Barriers

1. To assess prenatal genetic counselors’ practices regarding the utilization of
prenatal microarray
2. To assess prenatal genetic counselors’ perceived barriers regarding prenatal
microarray

Members: Nevena Krstic, Blair Stevens, Sarah Jane Noblin, Dr. Ramesha Papanna,
Dr. David Rodriguez

Do you consent to moving forward with the survey?
a. Yes, I wish to participate
b. No, I do not wish to participate

1. Do you provide prenatal genetic counseling?
a. Yes
b. No
If No Selected, Then Skip to End of Survey

2. Do you discuss prenatal diagnostic testing options, such as chorionic villus
sampling (CVS) and amniocentesis, with patients?
a. Yes
b. No
If No Selected, Then Skip to End of Survey

3. Currently, how much of your time is spent counseling patients in the clinical
prenatal setting?
a. 0%
b. 1-20%
c. 21-40%
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d. 41-60%
e. 61-80%
f. 81-100%
If 0% Selected, Then Skip to End of Survey

4. Approximately how many prenatal patients do you see per week, including both
new and follow-up patients?
a. <5
b. 6-10
c. 11-15
d. 16-20
e. >20
5. How many years of total genetic counseling experience do you have?
a. <5
b. 6-10
c. 11-15
d. 16-20
e. >20
6. How many years have you worked in the clinical prenatal setting?
a. <5
b. 6-10
c. 11-15
d. 16-20
e. >20
7. What region do you currently practice in?
a. Region 1: CT, MA, ME, NH, NY, RI, VT, CN, Maritime Provinces
b. Region 2: DC, DE, MD, NJ, NY, PA, VA, WV, PR, VI, Quebec
c. Region 3: AL, FL, GA, KY, LA, MS, NC, SC, TN
d. Region 4: AR, IA, IL, IN, KS, MI, MN, MO, ND, NE, OH, OK, SD, WI,
Ontario
e. Region 5: AZ, CO, MT, NM, TX, UT, WY, Alberta, Manitoba,
Saskatchewan
f. Region 6: AK, CA, HI, NV, ID, OR, WA, British Columbia
8. What type of setting do you currently work in?
a. University Medical Center/Academic Institution
b. Private Hospital/Medical Facility
c. Public Hospital/Medical Facility
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d.
e.
f.
g.

Government or Military Hospital/Medical Facility
Private Practice/Office
Commercial Diagnostic Laboratory
Other (Please Specify):__________

9. In your primary work setting, roughly what percentages of your patients are in
the following groups? (Please approximate; groups may not sum up to 100%)
0%

1-9%

10-24%

25-49%

50-74%

75100%

Private Insurance
Medicaid
Other State Health
Insurance (ie. CHIP)
Self Pay
Other (please specify):

10. How many prenatal genetic counselors, other than yourself, currently work in
your institution?
a. None, I am the only prenatal genetic counselor in my institution
b. 1-5
c. 6-10
d. 11-15
e. >15
11. Do you currently work in a center that provides fetal interventions such as inutero spina bifida repair, twin-to twin transfusion laser surgery, etc.?
a. Yes
b. No
c. Unsure
12. Are you directly involved in counseling patients who are evaluated for and/or
are candidates for fetal intervention?
a. Yes, I am directly involved
b. No, I am not directly involved
c. No, I am not directly involved but I refer patients who are evaluated for
fetal intervention
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13. What statement best describes your current level of knowledge regarding
prenatal microarray?
a. I am an expert and can teach others about it
b. I am comfortable ordering the test without further education
c. I am comfortable ordering the test, but desire more education
d. I know the basics of the test but am not comfortable ordering it
e. I do not know anything about the test
14. Are you familiar with current clinical guidelines for use of prenatal microarray?
a. Yes
b. No
c. Unsure
15. Do you work for a hospital, laboratory, or commercial entity that also performs
prenatal microarray?
a.

Yes

b. No
c. Unsure

16. Please indicate to what extent you agree or disagree with the following
statements:
Disagree

Somewhat
Disagree

I believe
prenatal
microarray
should be
offered to all
women,
regardless of
indication or
pursuit of
invasive testing

o

o

I believe that in
its current form,
the benefits of

o

o

Neither
Agree nor
Disagree
o

o

Somewhat
Agree

Agree

o

o

o

o
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prenatal
microarray
outweigh the
harms

17. Have you incorporated prenatal microarray into your clinical practice by
offering it as an option?
a. Yes
b. No

If yes, skip to question 20
If no continue to next question

18. When do you anticipate that you or your institution will begin offering prenatal
microarray in your clinical practice?
a. I do not plan to offer prenatal microarray in my clinical practice
b. Within the next 6 months
c. Within the next year
d. More than 1 year from now
e. Unsure
19. To what degree do the following factors play a role in why prenatal microarray
has not been offered in your clinical practice?

Financial Concerns
(Cost, insurance
coverage, etc.)
Possibility of
uncertain/ambiguous
results
Difficulty of interpreting
results (ie.VUS,
incidental findings)

No
Influence
o

Low Degree
o

Moderate
Degree
o

High
Degree
o

o

o

o

o

o

o

o

o
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Lack of knowledge or
data regarding
yield/utility
Patient specific
concerns (health
literacy, anxiety, etc.)
Time constraints/lack of
support staff
Other (please specify):

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

End of Survey

20. Please select the frequency with which you offer prenatal microarray given
the following indication:

Never

Rarely

About half
the time

Most of
the time

Always

All patients undergoing
prenatal genetic
counseling

o

o

o

o

o

Patients undergoing
invasive testing,
regardless of indication
Patients with structural
fetal anomalies
(ie. cardiac; renal)
Patients with nonstructural fetal
anomalies
(ie. soft signs; IUGR;
polyhydramnios)
Patients of advanced
maternal age (AMA)

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

Patients with a positive
screening for fetal
aneuploidy

o

o

o

o

o
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(ie. NIPT or serum
screening)
Patients with a positive
NIPT for
microdeletion/duplication
Patients with a personal
or family history of
microdeletion/duplication
Patients presenting with
fetal demise/stillbirth
Patients with a desire to
know “all information
possible”
Other (please specify):

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

21. To what degree do the following factors play a role when prenatal microarray is
not offered to the patient?

No Influence Low Degree
Financial Concerns
(Cost, insurance
coverage, etc.)
Difficulty of interpreting
results (ie. VUS,
incidental findings)
Lack of data regarding
yield/utility
Patient specific
concerns (health
literacy, anxiety, etc.)
Time constraints/lack of
support staff
Other (please specify):

Moderate
Degree
o

High
Degree
o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o
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22. Approximately how many times have you ordered prenatal microarray in the
last year?
a. 0
b. 1-5
c. 6-10
d. >10

23. Please select the frequency with which you order the following:

Never

Rarely

Targeted array

o

o

Expanded array

o

o

About half
the time
o
o

Most of Always
the time
o
o
o

o

24. Please select the frequency with which you order the following:

Never

Rarely

Array only

o

o

Array with full karyotype

o

o

Array with limited/5 cell
count karyotype

o

o

About half
the time
o
o
o

Most of Always
the time
o
o
o

o

o

o

25. What type of array do you most frequently order?
a. Oligonucleotide array
b. SNP array
c. Combination (oligo and SNP) array
d. Unsure
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26. At present, how is informed consent for prenatal microarray obtained in your
clinic?
a. Verbal consent
b. Written consent
c. Verbal and written consent
d. Other (please specify):___________

27. Has the amount of time it takes to complete a genetic counseling session
changed with implementation of prenatal microarray into your practice?
a. Yes, it has become longer
b. Yes, it has become shorter
c. No change
d. Varies based on case/clinical situation
e. Unsure
28. How frequently do you discuss the following during pre-test counseling for
prenatal microarray?

Never
Result may be
abnormal/pathogenic
Result may be
abnormal/pathogenic
but the nature or
severity of the
defects/disease may
not be predictable
Result may indicate an
adult onset disorder
Result may have
implications for one or
both of the parents

Rarely

About half
the time

Most of
the time

Always

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o
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Result may be a variant
of unknown significance
(VUS/VOUS)
Result may be an
incidental finding (nonpaternity,
consanguinity, incest,
etc.)
Cost and insurance
coverage

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

29. Do you or your institution participate in data sharing (ie. ClinGen)?
a. Yes
b. No
c. Unsure
30. What resources do you use to stay current on information about prenatal
microarray?
Select all that apply
__Guidelines or Practice Bulletins from Professional Organizations
__Peer-reviewed journals
__Review articles by experts on the topic
__National or scientific meetings
__Marketing material from commercial laboratories
__Other (please specify):_____________
__None of the above

Thank you for taking part in this survey. If you wish to take part in the drawing for 2
$50 Amazon gift cards please email Leslie.Durham@uth.tmc.edu with the subject
line microarray drawing. Your survey responses will not be linked to your email.
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